Catalyst Dossier · compiled by CeliA 🧫

Arcutis Biotherapeutics, Inc. (ARQT)

Pharmaceutical Preparations · market cap $3.3B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Arcutis Biotherapeutics (ARQT) is a commercial-stage dermatology company with 342 employees and a ~$3.4B market cap, built around topical roflumilast formulations targeting psoriasis, atopic dermatitis, seborrheic dermatitis, and chronic hand eczema. The company crossed into meaningful revenue in 2025 ($376M), sharply narrowing net losses from -$262M in 2023 to -$16M in 2025, though it carries net debt of $82.6M against only $34.8M in cash. A PDUFA event occurred on 2026-06-20 with an unknown outcome as of this writing, making near-term label decisions a live risk.

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Roflumilast Cream 0.3%	Phase 2	Plaque Psoriasis
Topical roflumilast	Phase 3	Chronic Plaque Psoriasis
ARQ-252 cream 0.3%	Phase 2	Chronic Hand Eczema
ARQ-151 Active	Phase 3	Atopic Dermatitis Eczema
Roflumilast Cream 0.15%	Phase 3	Atopic Dermatitis Eczema
Roflumilast Cream 0.05%	Phase 3	Atopic Dermatitis
ARQ-151 cream 0.5%	Phase 2	Psoriasis
ARQ-151 cream 0.05%	Phase 2	Atopic Dermatitis (Eczema)
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Phase 3	Atopic Dermatitis Eczema
ARQ-151 cream 0.3%	Phase 2	Psoriasis
Roflumilast 0.3% cream	Phase 3	Chronic Plaque Psoriasis
Roflumilast	Phase 2	Plaque Psoriasis
Roflumilast Foam 0.3%	Phase 3	Scalp Psoriasis
ARQ-154	Phase 2	Seborrheic Dermatitis
ARQ-151 0.3% cream	Phase 3	Chronic Plaque Psoriasis
Roflumilast Foam	Phase 3	Seborrheic Dermatitis
Roflumilast Cream	Phase 3	Atopic Dermatitis Eczema

Price & technical context

3-month

+9.7%

6-month

-9.5%

12-month

+87.9%

52-wk range

$13.39–$31.20

vs 50-day MA

+11.8%

vs 200-day MA

+6.0%

Realized vol

58.6%

Max drawdown

-37.5%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ARQT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.